A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database

Tirzepatide is a novel drug for the treatment of type 2 diabetes mellitus and chronic weight management, and there is an urgent need to explore its safety profile. The FDA Adverse Event Reporting System (FAERS) database provides a reliable pathway for adverse event (AE) disproportionality analysis....

Descrición completa

Detalles Bibliográficos

Principais autores:	Jie Li, Jun Xie, Yi Han, Wei Zhang, Yilei Wang, Zhitao Jiang
Formato:	Artigo
Idioma:	Inglês
Publicado:	The Japan Endocrine Society 2025-03-01
Series:	Endocrine Journal
Assuntos:	tirzepatide gip/glp-1 ra disproportionality analysis fda adverse event reporting system (faers) adverse drug event
Acceso en liña:	https://www.jstage.jst.go.jp/article/endocrj/72/3/72_EJ24-0286/_html/-char/en
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!